Eyeing US market, Samsung applies for approval of biosimilar Remicade

South Korean rival Celltrion recently won FDA approval for its own copy of the blockbuster anti-inflammatory drug. 

By Ned Pagliarulo • May 24, 2016

Sanofi diabetes chief to leave company as US business struggles

Competition and a tougher payer environment have led to lower sales from the important diabetes division. 

By Nicole Gray • May 24, 2016

Explore the Trendline➔

Commercialization

New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.

By BioPharma Dive staff

China slashes prices of top-selling cancer, hep B drugs

The price cuts, which are at least 50%, were agreed upon by the central government and drug makers after negotiations. 

By Nicole Gray • May 23, 2016

EMA removes warning from Pfizer smoking cessation drug

A major post-marketing study recently showed use of Chantix did not increase the risk of neuropsychiatric side effects. 

By Ned Pagliarulo • May 23, 2016

Novartis' Entresto gets boost from leading US cardiology groups

The American College of Cardiology, the American Heart Association and the Heart Failure Society of America have jointly updated guidelines giving the drug a class one recommendation for management of heart failure. 

By Nicole Gray • May 23, 2016

As big pharma moves in, biotech Galectin looks to stake claim to NASH market

NASH, a fatty liver disease, has grown in prevalence, with some saying it will replace hepatitis C as the main cause of liver transplantation by 2020. 

By Nicole Gray • May 18, 2016

Everyday low price? Walmart teams with McKesson to source generics

The companies say they hope the deal will add both scale and value to their existing distribution agreement. 

By Nicole Gray • May 18, 2016

Orexigen struggles to stay afloat as obesity market stagnates

After slow sales of Contrave last year and the exit of its co-marketing partner Takeda, Orexigen is predicting "zero-to-limited" growth for its obesity drug. 

By Nicole Gray • May 18, 2016

Novartis debates how to crack sales code for CAR-T therapy

No therapies have been approved yet, but their expected high cost and complex distribution process could require alternative marketing frameworks.

By Nicole Gray • May 17, 2016

After criticism, Valeant details plans for hospital discounts on heart drugs

Although the company had promised discounts on Nitropress and Isuprel earlier this year, a Senate committee investigation found few hospitals had actually received any relief. 

By Ned Pagliarulo • May 16, 2016

Regneron CEO counters criticism from ICER on pricing

The Boston-based Institute of Clinical and Economic Research (ICER) has become a prominent value-based-analysis think tank in Boston -- but not everyone is buying their claims. 

By Nicole Gray • May 13, 2016

Cigna signs value-based pricing deals with Amgen, Sanofi for PCSK9 drugs

Under the separate agreements, prices for the cholesterol-lowering drugs Repatha and Praluent will be linked to patient outcomes. 

By Nicole Gray • May 12, 2016

Opko Health's quest to redefine treatment for secondary HPT

BioPharma Dive spoke to a pair of company executives about their strategy to address a major challenge faced by patients with chronic kidney disease.

By Nicole Gray • May 12, 2016

Colombian diplomat warns of fallout from Novartis patent battle

In a leaked memo, a Colombian official warned his government that U.S. support for a peace initiative could be harmed if Colombia issues a patent override for Novartis' Gleevec. 

By Ned Pagliarulo • May 11, 2016

GSK's lupus drug finally wins NICE backing, but only after discounts

The British cost agency had rejected the drug in 2011 due to concerns over efficacy and price.

By Nicole Gray • May 11, 2016

Americans may have overspent billions on brand-name drugs, study finds

Increased therapeutic substitution by physicians would have sharply lowered costs in the two-year period studied, researchers said. 

By Nicole Gray • May 11, 2016

India awards patent to Gilead's Sovaldi

Patient advocacy and humanitarian groups had opposed Gilead's efforts to win protection for the hepatitis C treatment, claiming a patent would hurt patient access to affordable generic copies. 

By Ned Pagliarulo • May 10, 2016

FDA flags potential safety risk for Lilly antipsychotic drug

In rare cases, olanzapine can cause a serious, and sometimes fatal, skin reaction. 

By Ned Pagliarulo • May 10, 2016

Wave Life Sciences touts more effective Duchenne drug

Just last week, Pfizer and Wave agreed to a potentially $911 million deal for advancing development of several genetic therapies for metabolic diseases.

By Nicole Gray • May 10, 2016

U.K. cost agency recommends new PCSK9 drugs, but only after further discounts

Amgen's Repatha, and Sanofi/Regeneron's Praluent have had disappointing launches so far, despite their efficacy in lowering cholesterol levels. 

By Nicole Gray • May 9, 2016

ICER questions high prices of multiple myeloma meds

A number of new drugs have come onto the market recently, including Johnson & Johnson's Darzalex and Amgen's Kyprolis. 

By Nicole Gray • May 9, 2016

Clovis shuts down cancer drug, will reduce staff by 35%

Last month, an FDA panel had overwhelmingly voted against recommending approval for Clovis' rociletinib. 

By Nicole Gray • May 6, 2016

Regeneron reports strong Q1, but key drug faces pressure

PCSK9 drug Praluent generated only $13 million in Q1 sales—lower than the company had hoped.

By Nicole Gray • May 6, 2016

New Zealand pushes back on coverage for Merck's Keytruda

Adding to Merck's challenges in the country, the cost agency Pharmac has proposed funding for rival Bristol-Myers' Opdivo. 

By Nicole Gray • May 5, 2016

Bayer's Xarelto projected to become top-selling drug in Europe by 2022

Although Xarelto is an older drug, expanded indications and a new reversal agent could boost sales in Europe. Globally, however, the drug is predicted to fall well out of the top-ten drugs by sales. 

By Nicole Gray • May 4, 2016